Identification of a novel non-retinoid pan inverse agonist of the retinoic acid receptors

Scott A. Busby, Naresh Kumar, Dana S. Kuruvilla, Monica A. Istrate, Juliana J. Conkright, Yongjun Wang, Theodore M. Kamenecka, Michael D. Cameron, William R. Roush, Thomas P. Burris, Patrick R. Griffin

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Retinoids are potent forms of vitamin A and are involved in a broad range of physiological processes and the pharmacological effects of retinoids are primarily mediated by the retinoic acid receptors (RARs) and the retinoid X receptors (RXRs). Several natural and synthetic RAR modulators have proven to be clinically useful for a number of therapeutic indications including cancer, psoriasis, and diabetes. Unfortunately, these agents lead to a number of significant side effects. Most synthetic retinoid ligands are based on the retinoid scaffold and thus have similarities to the natural ligand with all previously disclosed RAR ligands having a carboxylic acid that makes a critical ionic bridge within the ligand binding domain of the receptors. The potential therapeutic value offered from RAR modulation provides the impetus to identify novel ligands based on unique scaffolds that may offer improved toxicity and pharmacokinetic profiles. Here we describe the identification of an atypical RAR inverse agonist that represents the first non-acid, non-retinoid direct modulator of RAR receptor subfamily. SR-0065 functions as a pan-RAR inverse agonist suppressing the basal activity of RARα, RARβ, and RARγ, as well as inhibiting agonist-induced RAR activity. SR-0065 treatment enhanced receptor interaction with a peptide representative of the corepressor SMRT, and in cells SR-0065 enhances recruitment of SMRT to the promoter of the RARγ dependent gene, Cyp26A1. The acid form of SR-0065, SR-1758, was inactive in all assays. Thus, SR-0065 represents a new class of non-acid, non-retinoid RAR modulator that may be used as a point to initiate development of improved RAR-targeted drugs.

Original languageEnglish (US)
Pages (from-to)618-627
Number of pages10
JournalACS Chemical Biology
Volume6
Issue number6
DOIs
StatePublished - Jun 17 2011

Fingerprint

Retinoic Acid Receptors
Retinoids
Ligands
Modulators
Scaffolds
Physiological Phenomena
Retinoid X Receptors
Co-Repressor Proteins
Pharmacokinetics
Medical problems
Carboxylic Acids
Vitamin A
Psoriasis
Toxicity

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine

Cite this

Busby, S. A., Kumar, N., Kuruvilla, D. S., Istrate, M. A., Conkright, J. J., Wang, Y., ... Griffin, P. R. (2011). Identification of a novel non-retinoid pan inverse agonist of the retinoic acid receptors. ACS Chemical Biology, 6(6), 618-627. https://doi.org/10.1021/cb100396s

Identification of a novel non-retinoid pan inverse agonist of the retinoic acid receptors. / Busby, Scott A.; Kumar, Naresh; Kuruvilla, Dana S.; Istrate, Monica A.; Conkright, Juliana J.; Wang, Yongjun; Kamenecka, Theodore M.; Cameron, Michael D.; Roush, William R.; Burris, Thomas P.; Griffin, Patrick R.

In: ACS Chemical Biology, Vol. 6, No. 6, 17.06.2011, p. 618-627.

Research output: Contribution to journalArticle

Busby, SA, Kumar, N, Kuruvilla, DS, Istrate, MA, Conkright, JJ, Wang, Y, Kamenecka, TM, Cameron, MD, Roush, WR, Burris, TP & Griffin, PR 2011, 'Identification of a novel non-retinoid pan inverse agonist of the retinoic acid receptors', ACS Chemical Biology, vol. 6, no. 6, pp. 618-627. https://doi.org/10.1021/cb100396s
Busby, Scott A. ; Kumar, Naresh ; Kuruvilla, Dana S. ; Istrate, Monica A. ; Conkright, Juliana J. ; Wang, Yongjun ; Kamenecka, Theodore M. ; Cameron, Michael D. ; Roush, William R. ; Burris, Thomas P. ; Griffin, Patrick R. / Identification of a novel non-retinoid pan inverse agonist of the retinoic acid receptors. In: ACS Chemical Biology. 2011 ; Vol. 6, No. 6. pp. 618-627.
@article{8049257b14bb4a938d665becddb38723,
title = "Identification of a novel non-retinoid pan inverse agonist of the retinoic acid receptors",
abstract = "Retinoids are potent forms of vitamin A and are involved in a broad range of physiological processes and the pharmacological effects of retinoids are primarily mediated by the retinoic acid receptors (RARs) and the retinoid X receptors (RXRs). Several natural and synthetic RAR modulators have proven to be clinically useful for a number of therapeutic indications including cancer, psoriasis, and diabetes. Unfortunately, these agents lead to a number of significant side effects. Most synthetic retinoid ligands are based on the retinoid scaffold and thus have similarities to the natural ligand with all previously disclosed RAR ligands having a carboxylic acid that makes a critical ionic bridge within the ligand binding domain of the receptors. The potential therapeutic value offered from RAR modulation provides the impetus to identify novel ligands based on unique scaffolds that may offer improved toxicity and pharmacokinetic profiles. Here we describe the identification of an atypical RAR inverse agonist that represents the first non-acid, non-retinoid direct modulator of RAR receptor subfamily. SR-0065 functions as a pan-RAR inverse agonist suppressing the basal activity of RARα, RARβ, and RARγ, as well as inhibiting agonist-induced RAR activity. SR-0065 treatment enhanced receptor interaction with a peptide representative of the corepressor SMRT, and in cells SR-0065 enhances recruitment of SMRT to the promoter of the RARγ dependent gene, Cyp26A1. The acid form of SR-0065, SR-1758, was inactive in all assays. Thus, SR-0065 represents a new class of non-acid, non-retinoid RAR modulator that may be used as a point to initiate development of improved RAR-targeted drugs.",
author = "Busby, {Scott A.} and Naresh Kumar and Kuruvilla, {Dana S.} and Istrate, {Monica A.} and Conkright, {Juliana J.} and Yongjun Wang and Kamenecka, {Theodore M.} and Cameron, {Michael D.} and Roush, {William R.} and Burris, {Thomas P.} and Griffin, {Patrick R.}",
year = "2011",
month = "6",
day = "17",
doi = "10.1021/cb100396s",
language = "English (US)",
volume = "6",
pages = "618--627",
journal = "ACS Chemical Biology",
issn = "1554-8929",
publisher = "American Chemical Society",
number = "6",

}

TY - JOUR

T1 - Identification of a novel non-retinoid pan inverse agonist of the retinoic acid receptors

AU - Busby, Scott A.

AU - Kumar, Naresh

AU - Kuruvilla, Dana S.

AU - Istrate, Monica A.

AU - Conkright, Juliana J.

AU - Wang, Yongjun

AU - Kamenecka, Theodore M.

AU - Cameron, Michael D.

AU - Roush, William R.

AU - Burris, Thomas P.

AU - Griffin, Patrick R.

PY - 2011/6/17

Y1 - 2011/6/17

N2 - Retinoids are potent forms of vitamin A and are involved in a broad range of physiological processes and the pharmacological effects of retinoids are primarily mediated by the retinoic acid receptors (RARs) and the retinoid X receptors (RXRs). Several natural and synthetic RAR modulators have proven to be clinically useful for a number of therapeutic indications including cancer, psoriasis, and diabetes. Unfortunately, these agents lead to a number of significant side effects. Most synthetic retinoid ligands are based on the retinoid scaffold and thus have similarities to the natural ligand with all previously disclosed RAR ligands having a carboxylic acid that makes a critical ionic bridge within the ligand binding domain of the receptors. The potential therapeutic value offered from RAR modulation provides the impetus to identify novel ligands based on unique scaffolds that may offer improved toxicity and pharmacokinetic profiles. Here we describe the identification of an atypical RAR inverse agonist that represents the first non-acid, non-retinoid direct modulator of RAR receptor subfamily. SR-0065 functions as a pan-RAR inverse agonist suppressing the basal activity of RARα, RARβ, and RARγ, as well as inhibiting agonist-induced RAR activity. SR-0065 treatment enhanced receptor interaction with a peptide representative of the corepressor SMRT, and in cells SR-0065 enhances recruitment of SMRT to the promoter of the RARγ dependent gene, Cyp26A1. The acid form of SR-0065, SR-1758, was inactive in all assays. Thus, SR-0065 represents a new class of non-acid, non-retinoid RAR modulator that may be used as a point to initiate development of improved RAR-targeted drugs.

AB - Retinoids are potent forms of vitamin A and are involved in a broad range of physiological processes and the pharmacological effects of retinoids are primarily mediated by the retinoic acid receptors (RARs) and the retinoid X receptors (RXRs). Several natural and synthetic RAR modulators have proven to be clinically useful for a number of therapeutic indications including cancer, psoriasis, and diabetes. Unfortunately, these agents lead to a number of significant side effects. Most synthetic retinoid ligands are based on the retinoid scaffold and thus have similarities to the natural ligand with all previously disclosed RAR ligands having a carboxylic acid that makes a critical ionic bridge within the ligand binding domain of the receptors. The potential therapeutic value offered from RAR modulation provides the impetus to identify novel ligands based on unique scaffolds that may offer improved toxicity and pharmacokinetic profiles. Here we describe the identification of an atypical RAR inverse agonist that represents the first non-acid, non-retinoid direct modulator of RAR receptor subfamily. SR-0065 functions as a pan-RAR inverse agonist suppressing the basal activity of RARα, RARβ, and RARγ, as well as inhibiting agonist-induced RAR activity. SR-0065 treatment enhanced receptor interaction with a peptide representative of the corepressor SMRT, and in cells SR-0065 enhances recruitment of SMRT to the promoter of the RARγ dependent gene, Cyp26A1. The acid form of SR-0065, SR-1758, was inactive in all assays. Thus, SR-0065 represents a new class of non-acid, non-retinoid RAR modulator that may be used as a point to initiate development of improved RAR-targeted drugs.

UR - http://www.scopus.com/inward/record.url?scp=79961090114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79961090114&partnerID=8YFLogxK

U2 - 10.1021/cb100396s

DO - 10.1021/cb100396s

M3 - Article

VL - 6

SP - 618

EP - 627

JO - ACS Chemical Biology

JF - ACS Chemical Biology

SN - 1554-8929

IS - 6

ER -